The latest NAV of WhiteOak Capital Pharma and Healthcare Fund – Direct Plan is ₹17.28 as of 2026-07-31.
The returns of WhiteOak Capital Pharma and Healthcare Fund – Direct Plan are 19.04% for 1 year, NA% for 3 years and NA% for 5 years, as per the latest available data. Investors should compare these returns with the category average and benchmark before making a decision.
The investment objective of WhiteOak Capital Pharma and Healthcare Fund – Direct Plan : The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.
WhiteOak Capital Pharma and Healthcare Fund – Direct Plan has a Very High risk rating as per the fund’s riskometer. Investors should check whether this risk level matches their investment horizon, financial goals and ability to handle market volatility.
The AUM, or Assets Under Management, of WhiteOak Capital Pharma and Healthcare Fund – Direct Plan is ₹741.34 crore. AUM indicates the total money managed under the scheme. Higher AUM may reflect investor confidence, but fund performance, consistency and portfolio quality should also be reviewed.
The expense ratio of WhiteOak Capital Pharma and Healthcare Fund – Direct Plan is 1.28. This is the annual fee charged by the fund house for managing the scheme. A lower expense ratio can help improve net returns over the long term, but it should not be the only factor used to judge a fund.